Pfizer (NYSE: PFE) EVP awarded 194,883 stock appreciation rights

Rhea-AI Filing Summary

MALIK AAMIR reported acquisition or exercise transactions in this Form 4 filing.

Pfizer executive vice president Aamir Malik received a grant of 194,883 stock appreciation rights on March 3, 2026. These derivative awards were granted at no cost and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant, subject to vesting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALIK AAMIR

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		194,883		03/03/2031(1)	03/03/2031(1)	Common Stock	194,883	$0.0000	194,883	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for Aamir Malik	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) report for Aamir Malik?

Pfizer reported a grant of 194,883 stock appreciation rights to executive vice president Aamir Malik. The award was made on March 3, 2026, at no cost, and will be settled in Pfizer common stock after vesting conditions are met on the fifth anniversary.

What type of securities did Aamir Malik receive from Pfizer (PFE)?

Aamir Malik received stock appreciation rights from Pfizer. These derivative awards track the value of Pfizer common stock and, once vested, will be settled in shares of Pfizer stock rather than cash, aligning executive compensation with long-term shareholder value.

How many Pfizer (PFE) stock appreciation rights were granted to Aamir Malik?

Aamir Malik was granted 194,883 stock appreciation rights by Pfizer. This entire amount was acquired in a single award on March 3, 2026, increasing his directly held derivative position to 194,883 stock appreciation rights following the transaction.

When will Aamir Malik’s Pfizer (PFE) stock appreciation rights settle?

The stock appreciation rights granted to Aamir Malik will settle on the fifth anniversary of the grant date. After meeting vesting requirements, they will be paid out in shares of Pfizer common stock, providing long-term equity exposure tied to Pfizer’s performance.

Are Pfizer (PFE) stock appreciation rights granted to Aamir Malik subject to vesting?

Yes, the stock appreciation rights granted to Aamir Malik are subject to vesting requirements. Only after those conditions are satisfied will the rights be settled, at which point Pfizer will deliver shares of common stock on the fifth anniversary of the grant date.

Did Aamir Malik pay a purchase price for the Pfizer (PFE) stock appreciation rights?

No, Aamir Malik did not pay a purchase price for these stock appreciation rights. The Form 4 indicates they were granted as a compensation award at a price per right of zero dollars, reflecting an equity-based incentive rather than an open-market purchase.